Home-based Transcranial Direct Current Stimulation (tDCS) to Promote Social Communication and Behaviour in Children With Autism Spectrum Disorder (ASD)

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age9-18
SponsorHolland Bloorview Kids Rehabilitation Hospital

About this trial

Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that can be delivered in a home setting. It is a safe and tolerable intervention that has shown promise for improving positive social communication and self-regulation in youth with Autism Spectrum Disorder (ASD). Children and youth with ASD will be randomized to At-home tDCS or sham control stimulation for 3 weeks. We will measure the effect of At-home tDCS on the brain mechanisms and clinical measures of social communication and self-regulation..

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Children with a diagnosis of autism spectrum disorder and self-regulation impairment or social communication challenges

Able to participate in tDCS

Disqualifiers

Children with contraindications to tDCS (history of seizures, family history of seizures, metal implants)

Co-existing neurological conditions (epilepsy, stroke, etc.)

Trial design

Design model

Parallel

Treatments tested in this trial

  • At-home transcranial direct current stimulation (tDCS)

    Device

    30 minutes session 5 days/week for 3 weeks.

  • Sham at-home tDCS

    Device

    30 minutes session 5 days/week for 3 weeks.

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: tDCSExperimental treatment 1 intervention
Group B: ShamSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Recruitment

Recruitment rates of 4 participants/month are achieved with a ≥ 20% response rate

Time frame
weeks 1-18
2

Attrition

Attrition rates of less than 10% (i.e., ≥90% of participants successfully complete assessments).

Time frame
weeks 1-18
3

Adherence

90% of participants who complete assessment achieve the target intensity and dose (15 tDCS sessions)

Time frame
weeks 1-18
4

Blinding

Blinding of participants and their parents/caregivers and required study team using a Blinding Questionnaire indicating the perceived group membershipmembers will be assessed using a Blinding Questionnaire indicating the perceived group membership (tDCS/Sham)

Time frame
weeks 1-18

Secondary outcomes

1

Magnetic Resonance Imaging (MRI)

Diffusion imaging - change in fractional anisotropy, Resting State functional MRI change in Blood Oxygen Level Dependent (BOLD) signal

Time frame
0 weeks, 6 weeks, 18 weeks
2

Inhibitory control

change in Go/No Task Response Time

Time frame
0 weeks, 6 weeks, 18 weeks
3

Overall Clinical Change

Clinical Global Impression scale - 1 item on a scale from 0-7 (a change of 0.5 indicates a clinical impact of significance)

Time frame
0 weeks, 6 weeks, 18 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.